Company Overview and News


Add LLY
to your dashboard

Headline News

Trump's nominee for top health job Alex Azar reaped millions from drug company

6h nzherald.co.nz
Newly disclosed financial records show that President Donald Trump's nominee to become secretary of the Health and Human Services Department reaped big earnings during his tenure as a top pharmaceutical executive. (2-0)

Your Daily Pharma Scoop: Geron's Fate, Celldex Commences Mid-Stage Study, Novartis's Tasigna

10h seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (141-0)

Celldex (CLDX) Initiates Phase II Study on Cancer Candidate

11h zacks
Celldex Therapeutics, Inc. (CLDX - Free Report) announced the initiation of a phase II study on its human monoclonal antibody, CDX-3379 in patients with advanced head and neck squamous cell carcinoma ("HNSCC"). (35-0)

Industry Group Rank Restrict Eli Lilly (LLY) Rating

2017-11-17 investorplace
Eli Lilly and Company (NYSE:LLY) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top decile of sector group, Health Care, with a market value of $91.7 billion. From an investment attractiveness viewpoint, LLY is ranked in the top half of the sector with a ranking of 274 among the 782 companies in the sector; Portfolio Grader's current ranking for LLY puts it 38 among the 132 companies in this industry group, placing it in the top half and number 1,727 in the 5000 company Portfolio Grader company universe. (2-0)

Cancer Space Update: Label Expansion for Three Major Drugs

2017-11-17 zacks
With a busy earnings season almost coming to an end after an impressive run, we are again focused on latest cancer updates happening every week. The week gone by saw three cancer drugs receiving FDA approval for new indications – Roche Holding AG’s (RHHBY - Free Report) Gazyva, Pfizer Inc.’s (PFE - Free Report) Sutent and AstraZeneca PLC’s (AZN - Free Report) Faslodex. However, an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck (MRK - Free Report) are working on. (396-1)

Analyzing $CERC – TickerJunkie

2017-11-17 tickerjunkie
Cerecor Inc. is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. Through this write-up, I will be covering the management team, pipeline, insider transactions and future growth. (68-0)

Novo Nordisk: Q3 2017 Results Show Strong Future Potential

2017-11-17 seekingalpha
While the company has been growing both sales and profits YOY, it is the non-North American segment delivering almost all of the growth. (2-0)

AstraZeneca’s Valuation after 3Q17 Earnings

2017-11-16 marketrealist
AstraZeneca (AZN) is a leading pharmaceutical company involved in developing and manufacturing drugs for primary care and specialty care. It operates in more than 100 countries. The company released its 3Q17 earnings on November 9, 2017. (3-0)

AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

2017-11-16 zacks
AstraZeneca, plc (AZN - Free Report) announced that the FDA has granted approval to a new indication for its breast cancer drug, Faslodex. (63-0)

Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

2017-11-16 zacks
With third quarter earnings season drawing to a close, the focus is back on deals, regulatory approvals and pipeline updates. This week, companies like AstraZeneca (AZN - Free Report) and Bayer (BAYRY - Free Report) were in the news with the former announcing the FDA approval of its severe asthma drug while Bayer signed a cancer-focused deal with Loxo Oncology. Recap of the Week’s Most Important Stories FDA Approval for AstraZeneca Severe Asthma Drug: AstraZeneca continues to deliver on its pipeline with the company scoring a couple of FDA nods this week. (149-0)

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

2017-11-16 reuters
LONDON (Reuters) - Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain’s state-funded health service. (2-0)

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

2017-11-16 channelnewsasia
Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service. (2-0)

9 Must-Own Stocks That Have Paid Over a Century of Dividends | InvestorPlace

2017-11-15 investorplace
Dividend stock investing is inherently a long-term enterprise. After all, companies only pay their investors dividends once a quarter and dividend yields are calculated on an annualized basis. If you own a stock for only a few months, you’re not experiencing the full dividend potential. And if you only own a few weeks, there’s a chance you don’t get paid a dividend at all. (55-0)

J&J Presents Positive New Data for Diabetes Drug Invokana

2017-11-15 zacks
Johnson & Johnson (JNJ - Free Report) presented new data from a large CANVAS outcomes program on its type II diabetes drug, Invokana (SGLT2 inhibitor), demonstrating an improved renal outcome. The data was presented at the annual meeting of the American Heart Association Scientific Sessions in California and published in the Circulation. (10-0)

Outsiders Can't Transform a Bureaucracy - Bloomberg

2017-11-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (2-0)

CUSIP: 532457108